Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vortioxetine and THINC-it in MDD
NCT03053362Phase 3Completed
- Sponsor
- Brain and Cognition Discovery Foundation
- Start
- May 2017
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of vortioxetine in major depressive disorder (MDD) (2 arms), sponsored by Brain and Cognition Discovery Foundation. Primary endpoint: Cognition Measured Using the THINC-it Tool at 8 weeks. Started May 2017; status: completed.
02
Drugs
vortioxetine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT03053362.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03053362.